| 0.81 -0.03 (-3.57%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.19 | 1-year : | 1.37 |
| Resists | First : | 1.02 | Second : | 1.17 |
| Pivot price | 0.87  |
|||
| Supports | First : | 0.76 | Second : | 0.64 |
| MAs | MA(5) : | 0.84  |
MA(20) : | 0.87 |
| MA(100) : | 0.96 |
MA(250) : | 1.02 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.3 |
D(3) : | 18.4 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 1.5 | Low : | 0.43 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ONCY ] has closed above bottom band by 30.8%. Bollinger Bands are 9.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.88 - 0.89 | 0.89 - 0.89 |
| Low: | 0.79 - 0.79 | 0.79 - 0.8 |
| Close: | 0.8 - 0.81 | 0.81 - 0.82 |
Oncolytics Biotech Inc. is a biopharmaceutical firm in its development phase, concentrating its efforts on discovering and creating novel pharmaceutical agents to combat cancer. Its primary therapeutic candidate is pelareorep, an immunotherapeutic drug delivered intravenously, designed to target and treat both solid tumors and various blood-related cancers. The company has established strategic co-development agreements with major pharmaceutical companies, Merck KGaA and Pfizer Inc., as well as with PrECOG LLC. These collaborations are focused on advancing pelareorep for use in conjunction with paclitaxel and avelumab (a human anti-PD-L1 antibody). This specific combination therapy is being developed to address hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Oncolytics Biotech Inc. was founded in 1998 and is based in Calgary, Canada.
Fri, 05 Jun 2026
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Wed, 03 Jun 2026
Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding - Stock Titan
Wed, 03 Jun 2026
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06 - Stock Titan
Wed, 03 Jun 2026
Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options - Stock Titan
Wed, 03 Jun 2026
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director granted options on 30,000 shares at $1.06 - Stock Titan
Wed, 03 Jun 2026
ONCOLYTICS (ONCY) CFO receives 260,000 stock options at $1.06 exercise price - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 119 (M) |
| Shares Float | 114 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 7,270 (K) |
| Shares Short P.Month | 6,180 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -171 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -2.54 |
| PEG Ratio | 0 |
| Price to Book value | -20.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|